Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$830.70M
EBITDA Margin
-1761.78%
TTM Avg
-1761.78%
3Y Avg
-1761.78%
5Y Avg
-1761.78%
Market Cap
$812.73M
EBITDA Margin
-9.31%
TTM Avg
-8.54%
3Y Avg
-46.73%
5Y Avg
-472.39%
Market Cap
$808.29M
EBITDA Margin
12.02%
TTM Avg
14.44%
3Y Avg
-4.83%
5Y Avg
-238.26%
Market Cap
$853.77M
EBITDA Margin
-68.63%
TTM Avg
-68.17%
3Y Avg
-9114.49%
5Y Avg
-9114.49%
Market Cap
$847.33M
EBITDA Margin
-37.08%
TTM Avg
-66.80%
3Y Avg
-66.80%
5Y Avg
-66.80%
Market Cap
$798.22M
EBITDA Margin
18.47%
TTM Avg
18.88%
3Y Avg
13.21%
5Y Avg
14.52%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | $818.57M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $830.70M | -1761.78% | -1761.78% | -1761.78% | -1761.78% |
| Apnimed, Inc. (APMD)vs › | $824.34M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $812.73M | -9.31% | -8.54% | -46.73% | -472.39% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $808.29M | 12.02% | 14.44% | -4.83% | -238.26% |
| Beta Bionics, Inc. (BBNX)vs › | $853.77M | -68.63% | -68.17% | -9114.49% | -9114.49% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $847.33M | -37.08% | -66.80% | -66.80% | -66.80% |
| InMode Ltd. (INMD)vs › | $809.04M | 23.23% | 25.96% | 33.88% | 36.34% |
| AdaptHealth Corp. (AHCO)vs › | $798.22M | 18.47% | 18.88% | 13.21% | 14.52% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $868.65M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
